Editorial Disclosure: GLP-1 Editorial is an editorial publication operated by Ranika Editorial Group LLC. We do not provide medical care, prescribe medication, manufacture or compound medication, or sell GLP-1 treatment. Our rankings are based on our published v3.0 transparency rubric, publicly available provider information, cited sources, and periodic review updates. If a provider relationship, sponsorship, affiliate relationship, or material connection exists, it is disclosed on the relevant page and at /affiliate-disclosure.html.
Home · Clinical · Side Effects
Clinical Reference · Updated 2026-05-08

Side Effects

Most common: nausea (44%), diarrhea (30%), vomiting (24%), constipation (24%). Mostly mild-moderate and titration-dependent. Serious AEs <1% in published cohorts.

Clinical referencePubMed-linkedUpdated 2026-05-08
SS
Editorial team
Dr. Sam Saberian · Lead Medical Researcher
Medical review by Alen A. Schwartz, MD · Edited by Julliana Edwards · Last updated 2026-05-11

Overview

Most common: nausea (44%), diarrhea (30%), vomiting (24%), constipation (24%). Mostly mild-moderate and titration-dependent. Serious AEs <1% in published cohorts.

PubMed citations

Related clinical pages

Important medical and regulatory disclosure: Compounded semaglutide and compounded tirzepatide are not FDA-approved. They are not the same as Ozempic, Wegovy, Mounjaro, or Zepbound. Compounded medications may be prescribed only when clinically appropriate after review by a licensed medical provider. GLP-1 Editorial does not provide medical advice, prescribe medication, manufacture medication, or operate a pharmacy.